While Exagen Inc has underperformed by -2.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, XGN rose by 50.98%, with highs and lows ranging from $12.23 to $2.67, whereas the simple moving average fell by -20.36% in the last 200 days.
On September 11, 2025, B. Riley Securities started tracking Exagen Inc (NASDAQ: XGN) recommending Buy. A report published by KeyBanc Capital Markets on July 30, 2025, Upgraded its rating to ‘Overweight’ for XGN. Craig Hallum also rated XGN shares as ‘Buy’, setting a target price of $12 on the company’s shares in an initiating report dated July 23, 2025. Cowen initiated its ‘Outperform’ rating for XGN, as published in its report on October 15, 2021. Canaccord Genuity’s report from April 15, 2021 suggests a price prediction of $25 for XGN shares, giving the stock a ‘Buy’ rating. KeyBanc Capital Markets also rated the stock as ‘Overweight’.
Analysis of Exagen Inc (XGN)
Further, the quarter-over-quarter increase in sales is 37.87%, showing a positive trend in the upcoming months.
Exagen Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -122.81% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.81, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and XGN has an average volume of 329.08K. On a monthly basis, the volatility of the stock is set at 5.05%, whereas on a weekly basis, it is put at 6.25%, with a loss of -3.43% over the past seven days. Furthermore, long-term investors anticipate a median target price of $15.43, showing growth from the present price of $6.19, which can serve as yet another indication of whether XGN is worth investing in or should be passed over.
How Do You Analyze Exagen Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 32.38%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 43.88% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
